Morgan Stanley Downgrades QLT Inc (QLTI) to Underweight
More News related to QLTI
- QLT announces Toronto Stock Exchange approval of share repurchase program
- QLT Inc. (QLTI) reports Q3 EPS of $0.04
- QLT Inc. (QLTI) Reports Q3 Adj-Loss of $0.08; to Buyback Up to 5% of Shares
- QLT Announces Share Repurchase Program
- QLT Inc. (QLTI) Announces Simplified Novartis Pharma (NVS) Relationship; Will Have Exclusive Visudyne Rights
More News related to Downgrades
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
- Barrington Downgrades Perceptron (PRCP) Following Q1 Miss
- DA Davidson Issues Mid-Day Downgrade on FEI Company (FEIC)
- D.A. Davidson Downgrades Sterling Construction (STRL) to Neutral
- BMO Capital Downgrades MF Global (MF) to Market Perform
Morgan Stanley downgrades QLT Inc (Nasdaq: QLTI) from Equalweight to Underweight.
QLT Inc. is a global biopharmaceutical company with two commercial products, Visudyne and Eligard, which were derived from its two technology platforms, photodynamic therapy and Atrigel.
Related Categories
DowngradesStocks Mentioned
-0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
